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Abstract: A synthetic route to cis-2-methyl-4-oxo-6-alkylpiperidines has been developed using a 6-
endo-trig cyclization of E-enones. The base-mediated intramolecular cyclization was found to be 
general for both alkyl and aryl substituted enones, providing the corresponding 4-oxopiperidines in high 
yields (80–89%). Stereoselective reduction of the 2,6-cis-disubstituted 4-oxopiperidines then gave the 
2,4,6-cis,cis-trisubstituted 4-hydroxypiperidines in high diastereoselectivity. The general nature of this 
approach was demonstrated with the synthesis of the natural products, spruce alkaloid and (+)-241D. 
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The piperidine ring system is found as a key structural element in a vast array of natural products and 
pharmaceutically active compounds.1 Among the various structural classes, 2,6-cis-dialkylpiperidines 
have been isolated from plants, insects and amphibians and have demonstrated a wide range of 
biological activities.1 These include cis,cis-2-methyl-4-hydroxy-6-alkylpiperidines such as spruce 
alkaloid (1), isolated from the Colorado blue spruce, Picea pungens (Figure 1).2 Interestingly, the 
absolute configuration of spruce alkaloid (1) is not known. The structure was determined from GC-MS 
data, a racemic synthesis and analogy to similar 2,6-disubstituted piperidines from conifers, which 
generally possess the same absolute configuration at the C2-methyl center.2 Other examples of this class 
of alkaloid include (+)-241D (2), isolated from the skin of the Panamanian poison frog Dendrobates 
speciosus.3 (+)-241D (2) and the corresponding 4-piperidone 3 are potent inhibitors of binding of 
[3H]perhydrohistrionicotoxin to nicotinic acetylcholine receptor ion channels.4  
 
Figure 1. Structures of biologically active cis-2,6-disubstituted piperidines. 
 
 As a result of significant biological activity and the common cis,cis-2-methyl-4-hydroxy-6-
alkylpiperidine framework, there have been significant interest in developing approaches for the 
synthesis of these alkaloids. In particular, many strategies have been reported for the asymmetric 
synthesis of (+)-241D (2).5 These include a highly efficient, six-step approach reported by Ma and Sun 
involving the condensation of ethyl acetoacetate with a -amino ester, followed by hydrolytic 
decarboxylation and high pressure hydrogenation (Scheme 1a).6 This gave (+)-241D (2) in 46% overall 
yield. In contrast, only one asymmetric synthesis has been reported for the proposed structure of spruce 
alkaloid (1).7 Helmchen and co-workers used an iridium-catalyzed allylic cyclization, in combination 
with the matched pairing of a chiral allylic carbonate and a chiral phosphoramidite ligand as the key 
transformation in a fourteen-step synthesis of spruce alkaloid (1) (Scheme 1b). This approach was also 
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used for the preparation of other 2,6-cis-dialkylpiperidine alkaloids such as (+)-prosophylline and (+)-
241D.7  
In recent years, we have reported stereoselective methods for the synthesis of highly substituted 
pipecolic acid analogues using a 6-endo-trig cyclization of enone-derived -amino acids.8,9 We found 
that formation of a particular cyclization conformer using substrate control generated either 2,6-trans- or 
2,6-cis-6-substituted 4-oxopipecolic acids. We were interested in investigating a similar approach for 
the synthesis of cis-2-methyl-4-oxo-6-alkylpiperidines (Scheme 1c). Herein, we now report the use of a 
6-endo-trig cyclization of amine-substituted enones for the preparation of a series of 2-methyl-4-
hydroxy-6-alkylpiperidines and the application of this approach for the eight-step synthesis of spruce 
alkaloid and (+)-241D. 
 
Scheme 1. Methods for the Synthesis of cis,cis-2-Methyl-4-hydroxy-6-alkylpiperidines 
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A series of amine-substituted enones were prepared in five steps from commercially available N-Boc-
L-aspartic acid 4-methyl ester (4) (Scheme 2). The -carboxylic acid of 4 was reduced in a two-stage 
process involving activation with N-hydroxysuccinimide (NHS) and DCC, followed by reduction of the 
resulting succinimide ester with sodium borohydride.10 Direct conversion of alcohol 5 to iodide 6 was 
achieved using triphenylphosphine, imidazole and iodine under Tanner’s modified conditions.11 Basic 
hydrodehalogenation under mild conditions allowed the highly efficient synthesis of -homoalanine 
derivative 7. It should be noted that Hünig’s base is required during the hydrodehalogenation to 
neutralize the hydrogen iodide formed and prevent poisoning of the Pd/C catalyst.12 Reaction of 7 with 
the lithium anion of dimethyl methylphosphonate (2.5 equivalents) completed the four-step synthesis of 
-ketophosphonate ester 8 in 72% overall yield.13 It should be noted that this simple and robust four-
step synthesis was easily scalable for the efficient multigram synthesis of -ketophosphonate ester 8. 
Horner-Wadsworth-Emmons (HWE) reaction of 8 with various alkyl and aryl aldehydes gave the 
corresponding E-enones 9a–9h as the sole products in 63–97% yield.14  
 
Scheme 2. Synthesis of E-Enones 9a 
 
aIsolated yields are shown. 
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Enones 9 were then converted to 2,6-disubstituted 4-oxopiperidines 10 and 11 by acidic removal of 
the Boc-protecting group, followed by cyclization of the resulting amine by treatment with DIPEA 
(Table 1). In our previous study involving 6-endo-trig cyclization of -amino acid derived enones, the 
use of this two-step approach gave the corresponding 2,6-cis-6-substituted 4-oxopipecolic acids as the 
major products, although with modest diastereoselectivity.9 As expected of enones 9, with a smaller 
methyl group to impart facial selectivity during the conjugate addition, the 2,6-cis- and 2,6-trans-6-
substituted 4-oxopiperidines were formed in essentially a 1:1 ratio.15,16 However, these structurally more 
simple substrates were found to undergo the two-stage deprotection and cyclization in a highly efficient 
and general manner, forming the two diastereomers in highly consistent yields (80–89%), irrespective of 
the enone side-chain. Furthermore, 4-oxopiperidines 10 and 11 were easily separated by column 
chromatography, allowing the isolation of the 2,6-cis-diastereomer in 41–46% yields over two steps.  
 
Table 1. 6-Endo-Trig Cyclization of E-Enones 9a 
 
entry R overall yield (%) 10 (%) 11 (%) 
1 n-Pr (9a) 85 43 42 
2 n-nonyl (9b) 89 45 44 
3 CH2CH2Ph (9c) 82 42 40 
4 Ph (9d) 82 42 40 
5 p-MeOPh (9e) 83 46 37 
6 2-Naphth (9f) 86 44 42 
7 p-NO2Ph (9g) 84 43 41 
8 3-Py (9h) 80 41 39 
aIsolated yields are shown. 
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To complete the synthesis of spruce alkaloid (1) and (+)-241D (2) required the stereoselective 
reduction of the 2,6-cis-4-oxopiperidines. We briefly surveyed various reducing agents [e.g. L-
selectride, NaBH3CN and NaBH(OAc)3] and found that sodium borohydride was fast, selective and 
high yielding (Scheme 3).5d,17 In all cases, this gave a diastereoselective ratio of 9:1 with the major 
cis,cis-4-hydroxypiperidines isolated in 68–91% yields. This completed the total synthesis of spruce 
alkaloid (1) and (+)-241D (2) in eight steps and in 26% and 21% overall yield, respectively, as well as 
various novel cis,cis-2-methyl-4-hydroxy-6-arylpiperidines (12c–12f). The relative stereochemistry of 
all novel compounds generated from the 6-endo-trig cyclization and the stereoselective reduction was 
confirmed using NOE experiments.18   
 
Scheme 3. Stereoselective Reduction of 4-Piperidones 10a 
 
aIsolated yields of cis,cis-4-hydroxypiperidines are shown. 
 
 In summary, a short and efficient synthesis of a series of amino substituted E-enones was developed 
from an L-aspartic acid analogue using hydrodehalogenation and HWE reactions as the key steps. These 
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compounds were investigated as substrates for a base-mediated 6-endo-trig cyclization. The two-stage 
deprotection-cyclization process was highly efficient and tolerant of both aliphatic and aryl side chains. 
Stereoselective reduction of the resulting 2,6-cis-4-oxopiperidines completed a new approach for the 
preparation of the natural products, spruce alkaloid and (+)-241D, as well as the synthesis of a series of 
novel cis,cis-2-methyl-4-hydroxy-6-arylpiperidines.   
 
EXPERIMENTAL SECTION 
All reagents and starting materials were obtained from commercial sources and used as received. All 
dry solvents were purified using a solvent purification system. All reactions were performed in oven-
dried glassware under an atmosphere of argon unless otherwise stated. Brine refers to a saturated 
solution of sodium chloride. Flash column chromatography was performed using silica gel 60 (40–63 
m). Aluminium-backed plates pre-coated with silica gel 60F254 were used for thin layer 
chromatography and were visualized with a UV lamp or by staining with potassium permanganate. 1H 
NMR spectra were recorded on a NMR spectrometer at either 400 or 500 MHz and data are reported as 
follows: chemical shift in ppm relative to tetramethylsilane or the solvent as the internal standard 
(CDCl3,  7.26 ppm or CD3OD,  3.31 ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet or overlap of nonequivalent resonances, integration). 13C NMR spectra were 
recorded on a NMR spectrometer at either 101 or 126 MHz and data are reported as follows: chemical 
shift in ppm relative to tetramethylsilane or the solvent as internal standard (CDCl3,  77.0 ppm or 
CD3OD,  49.0 ppm), multiplicity with respect to hydrogen (deduced from DEPT experiments, C, CH, 
CH2 or CH3). IR spectra were recorded on a FTIR spectrometer; wavenumbers are indicated in cm
–1. 
Mass spectra were recorded using electrospray techniques. HRMS spectra were recorded using a dual-
focusing magnetic analyzer mass spectrometer. Melting points are uncorrected. Optical rotations were 
determined as solutions irradiating with the sodium D line (λ = 589 nm) using a polarimeter. [α]D values 
are given in units 10−1 deg cm2 g−1.   
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Methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate (5).19 To a solution of N-Boc-L-
aspartic acid 4-methyl ester (4) (8.27 g, 33.5 mmol) in ethyl acetate (200 mL) at 0 °C was added N-
hydroxysuccinimide (4.24 g, 36.9 mmol). N,N'-Dicyclohexylcarbodiimide (7.05 g, 34.2 mmol) in ethyl 
acetate (20 mL) was then added dropwise. The reaction mixture was allowed to warm to room 
temperature and stirred for 16 h. Once the reaction was complete, the reaction mixture was filtered 
through Celite. The filtrate was washed with saturated sodium carbonate solution (100 mL), brine (100 
mL), dried (MgSO4) and concentrated in vacuo. The resulting residue was then dissolved in 
tetrahydrofuran (20 mL) and added dropwise to a solution of sodium borohydride (2.03 g, 53.6 mmol) 
in a mixture of tetrahydrofuran and water (7.5:1, 85 mL). The reaction mixture was stirred for 0.1 h 
before quenching with saturated aqueous ammonium chloride (5 mL). The reaction mixture was 
extracted with dichloromethane (3 × 50 mL). The organic fractions were combined, washed with brine 
(100 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography on silica gel, eluting with 30% ethyl acetate in dichloromethane gave methyl (3S)-3-
(tert-butoxycarbonylamino)-4-hydroxybutanoate (5) as a colorless oil (7.03 g, 90%). Rf 0.22 (40% ethyl 
acetate in dichloromethane); [α]D26 +5.6 (c 1.0, CHCl3), lit.19 [α]D23 +6.3 (c 0.5, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 1.42 (s, 9H), 2.62 (d, J = 6.1 Hz, 2H), 2.82 (br s, 1H), 3.65–3.73 (m, 5H), 3.92–4.04 (m, 
1H), 5.25 (br s, 1H); 13C NMR (126 MHz, CDCl3) δ 28.4 (3 × CH3), 35.8 (CH2), 49.4 (CH), 51.9 (CH3), 
64.3 (CH2), 79.8 (C), 155.9 (C), 172.3 (C); MS (ESI) m/z 256 (MNa
+, 100). 
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (6).10 To a suspension of imidazole 
(4.11 g, 60.4 mmol) and triphenylphosphine (11.9 g, 45.3 mmol) in a mixture of diethyl ether and 
dichloromethane (2:1, 100 mL) at 0 °C was added iodine (11.5 g, 45.3 mmol) in three portions over 0.5 
h. After stirring for a further 0.2 h, a solution of methyl (3S)-3-(tert-butoxycarbonylamino)-4-
hydroxybutanoate (5) (7.03 g, 30.2 mmol) in a mixture of diethyl ether and dichloromethane (2:1, 50 
mL) was added and the resulting mixture was stirred for 3 h at room temperature. The reaction mixture 
was filtered through Celite and the filtrate was concentrated in vacuo. Purification by flash column 
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chromatography on silica gel, eluting with 30% diethyl ether in petroleum ether (40–60) gave methyl 
(3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (6) (9.33 g, 90%) as a colorless oil. Spectroscopic 
data were consistent with the literature.10 Rf 0.27 (20% ethyl acetate in petroleum ether); [α]D33 +7.3 (c 
1.0, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.40 (s, 9H), 2.60 (dd, J = 16.4, 6.1 Hz, 1H), 2.70 (dd, J = 
16.4, 5.6 Hz, 1H), 3.28–3.45 (m, 2H), 3.66 (s, 3H), 3.81–3.95 (m, 1H), 5.11 (d, J = 7.2 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 11.1 (CH2), 28.3 (3 × CH3), 38.5 (CH2), 47.7 (CH), 51.9 (CH3), 80.0 (C) 
154.7 (C), 171.1 (C); MS (ESI) m/z 366 (MNa+, 100). 
Methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (7).20 A solution of methyl (3S)-3-(tert-
butoxycarbonylamino)-4-iodobutanoate (6) (9.33 g, 27.2 mmol), N,N-diisopropylethylamine (7.11 mL, 
40.8 mmol) and 10% Pd/C (2.89 g, 2.72 mmol) in methanol (50 mL) were purged with hydrogen for 0.5 
h. The reaction mixture was stirred under an atmosphere of hydrogen for 18 h at room temperature. The 
mixture was then filtered through Celite and the filtrate was concentrated in vacuo. The resulting residue 
was dissolved in dichloromethane (100 mL) and washed with a saturated solution of sodium hydrogen 
carbonate (50 mL), 1 M hydrochloric acid (50 mL), brine (50 mL), dried over MgSO4, filtered and 
concentrated in vacuo to give methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (7) as a colorless oil 
(5.87 g, 99%). Spectroscopic data were consistent with the literature.20 Rf 0.17 (20% ethyl acetate in 
petroleum ether); [α]D26 +21.5 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.20 (d, J = 6.8 Hz, 3H), 
1.43 (s, 9H), 2.47 (dd, J = 15.5, 6.0 Hz, 1H), 2.52 (dd, J = 15.5, 5.4 Hz, 1H), 3.68 (s, 3H), 4.03 (br s, 
1H), 4.91 (br s, 1H); 13C NMR (126 MHz, CDCl3) δ 20.6 (CH3), 28.5 (3 × CH3), 40.8 (CH2), 43.6 (CH), 
51.8 (CH3), 79.4 (C), 155.2 (C), 172.1 (C); MS (ESI) m/z 240 (MNa
+, 100). 
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (8). Dimethyl 
methylphosphonate (3.74 mL, 34.5 mmol) was dissolved in tetrahydrofuran (100 mL) and cooled to −78 
°C under an argon atmosphere. n-Butyl lithium (2.5 M, in hexane, 13.8 mL, 34.5 mmol) was added 
dropwise and the mixture was stirred for 0.3 h. A solution of methyl (3R)-3-(tert-
butoxycarbonylamino)butanoate (7) (3.00 g, 13.8 mmol) in tetrahydrofuran (20 mL) was added 
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dropwise. The resulting mixture was then stirred at −78 °C for 0.5 h and allowed to warm to 0 °C over a 
period of 1 h. The reaction was quenched with a saturated aqueous solution of ammonium chloride (4 
mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were combined, washed 
with brine (100 mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by flash column 
chromatography on silica gel, eluting with 40% ethyl acetate in dichloromethane gave (4R)-4-(tert-
butoxycarbonylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (8) (3.84 g, 90%) as a colorless oil. Rf 
0.19 (100% ethyl acetate); IR (neat) 3316, 2976, 1704, 1700, 1248 cm−1; [α]D31 +38.3 (c 1.0, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 1.17 (d, J = 6.7 Hz, 3H), 1.39 (s, 9H), 2.71 (dd, J = 16.9, 5.9 Hz, 1H), 2.80 
(dd, J = 16.9, 5.9 Hz, 1H), 3.03 (dd, J = 22.6, 13.6 Hz, 1H), 3.12 (dd, J = 22.6, 13.6 Hz, 1H), 3.74 (d, J 
= 0.8 Hz, 3H), 3.77 (d, J = 0.8 Hz, 3H), 3.93–4.09 (m, 1H), 4.92 (br s, 1H); 13C NMR (101 MHz, 
CDCl3) δ 20.6 (CH3), 28.4 (3 × CH3), 41.9 (d, JC-P = 127.5 Hz, CH2), 43.3 (CH), 50.2 (CH2), 53.1 (d, JC-
O-P
 = 6.5 Hz, CH3), 53.2 (d, JC-O-P
 = 6.5 Hz, CH3), 79.3 (C), 155.2 (C), 200.6 (C); MS (ESI) m/z 332 
(MNa+, 100); HRMS (ESI) calcd for C12H24NNaO6P (MNa
+), 332.1233, found 332.1225.  
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (9a). (4R)-4-(tert-Butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (8) (0.421 g, 1.36 mmol) was dissolved in anhydrous acetonitrile 
(14 mL) and potassium carbonate (0.225 g, 1.63 mmol) was added. The mixture was stirred at room 
temperature for 0.5 h followed by addition of butyraldehyde (0.250 mL, 2.72 mmol). The temperature 
was increased to 50 °C and the mixture stirred for 72 h. The solution was then concentrated in vacuo, 
redissolved in ethyl acetate (20 mL), washed with water (2 × 15 mL) and then brine (15 mL). The 
organic layer was dried (MgSO4) and concentrated in vacuo. Purification using a plug of silica gel, 
eluting with 20% ethyl acetate in petroleum ether (40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-
4-oxonona-5-ene (9a) as a clear colorless oil (0.337 g, 97%). Rf 0.24 (20% ethyl acetate/petroleum 
ether); IR (neat) 3350, 2968, 1689, 1516, 1365 cm−1; [α]D26 +9.3 (c 1.0, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 0.94 (t, J = 7.3 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 1.43 (s, 9H), 1.46–1.55 (m, 2H), 2.20 (qd, J 
= 6.9, 1.5 Hz, 2H), 2.64 (dd, J = 15.9, 6.5 Hz, 1H), 2.86 (dd, J = 15.9, 4.5 Hz, 1H), 3.98–4.09 (m, 1H), 
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5.02 (br s, 1H), 6.09 (dt, J = 15.9, 1.5 Hz, 1H), 6.86 (dt, J = 15.9, 6.9 Hz, 1H); 13C NMR (126 MHz, 
CDCl3) δ 13.7 (CH3), 20.5 (CH3), 21.3 (CH2), 28.4 (3 × CH3), 34.5 (CH2), 43.7 (CH), 45.7 (CH2), 79.1 
(C), 130.8 (CH), 148.2 (CH), 155.2 (C), 199.2 (C); MS (ESI) m/z 278 (MNa+, 100); HRMS (ESI) calcd 
for C14H25NNaO3 (MNa
+), 278.1727, found 278.1725. 
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxopentadec-5-ene (9b). The reaction was carried out 
according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (8) (0.405 g, 1.31 mmol) and decanal (0.500 mL, 2.62 mmol) for 
96 h. Purification by flash column chromatography on silica gel, eluting with 30% diethyl ether in 
petroleum ether (40–60) gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxopentadec-5-ene (9b) (0.345 
g, 78%) as a colorless oil. Rf 0.25 (30% diethyl ether in petroleum ether); IR (neat) 3327, 2958, 1693, 
1365 cm−1; [α]D25 +4.2 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.3 Hz, 3H), 1.20 (d, J 
= 6.7 Hz, 3H), 1.23–1.34 (m, 12H), 1.39–1.50 (m, 11H), 2.20 (q, J = 7.0 Hz, 2H), 2.63 (dd, J = 15.7, 6.6 
Hz, 1H), 2.85 (dd, J = 15.7, 4.5 Hz, 1H), 3.96–4.08 (m, 1H), 4.95 (br s, 1H), 6.08 (d, J = 15.6 Hz, 1H), 
6.85 (dt, J = 15.6, 7.0 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.1 (CH3), 20.5 (CH3), 22.7 (CH2), 28.1 
(CH2), 28.4 (3 × CH3), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 31.9 (CH2), 32.5 (CH2), 43.7 
(CH), 45.7 (CH2), 79.2 (C), 130.6 (CH), 148.5 (CH), 155.2 (C), 199.2 (C); MS (ESI) m/z 362 (MNa
+, 
100); HRMS (ESI) calcd for C20H37NNaO3 (MNa
+), 362.2666, found 362.2649. 
(2R,5E)-8-Phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-ene (9c). The reaction was carried out 
according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (8) (0.349 g, 1.13 mmol) and hydrocinnamaldehyde (0.300 mL, 
2.26 mmol) for 48 h. Purification by flash column chromatography on silica gel, eluting with 20% ethyl 
acetate in petroleum ether (40–60) gave (2R,5E)-8-phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-
ene (9c) (0.288 g, 80%) as a pale yellow oil. Rf 0.19 (20% ethyl acetate in petroleum ether); IR (neat) 
3353, 2976, 1692, 1496, 1247, 1221, 1054 cm−1; [α]D23 +4.1 (c 1.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.17 (d, J = 6.7 Hz, 3H), 1.43 (s, 9H), 2.53 (q, J = 6.8 Hz, 2H), 2.60 (dd, J = 15.7, 7.8 Hz, 
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1H), 2.77 (t, J = 6.8 Hz, 2H), 2.84 (dd, J = 15.7, 4.5 Hz, 1H), 3.95–4.08 (m, 1H), 4.99 (br s, 1H), 6.09 
(d, J = 15.9 Hz, 1H), 6.87 (dt, J = 15.9, 6.8 Hz, 1H), 7.14–7.23 (m, 3H), 7.25–7.32 (m, 2H); 13C NMR 
(101 MHz, CDCl3) δ 20.5 (CH3), 28.4 (3 × CH3), 34.2 (CH2), 34.3 (CH2), 43.7 (CH), 45.8 (CH2), 79.1 
(C), 126.2 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 131.0 (CH), 140.6 (C), 146.9 (CH), 155.1 (C), 198.9 
(C); MS (ESI) m/z 340 (MNa+, 100); HRMS (ESI) calcd for C19H27NNaO3 (MNa
+), 340.1883, found 
340.1868. 
(2R,5E)-6-Phenyl-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9d). The reaction was carried out 
according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (8) (0.251 g, 0.810 mmol) and benzaldehyde (0.160 mL, 1.62 
mmol) for 48 h. Purification by flash column chromatography on silica gel, eluting with 20% ethyl 
acetate in petroleum ether (40–60) gave (2R,5E)-6-phenyl-2-(tert-butoxycarbonylamino)-4-oxohex-5-
ene (9d)  (0.227 g, 97%) as a white solid. Mp 59–62 °C; Rf 0.18 (20% ethyl acetate in petroleum ether); 
IR (neat) 3345, 2976, 1687, 1655, 1608, 1495 cm−1; [α]D23 +10.0 (c 1.0, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 1.25 (d, J = 6.8 Hz, 3H), 1.43 (s, 9H), 2.77 (dd, J = 15.8, 6.8 Hz, 1H), 3.00 (dd, J = 15.8, 4.6 
Hz, 1H), 4.05–4.18 (m, 1H), 5.04 (br s, 1H), 6.73 (d, J = 16.2 Hz, 1H), 7.36–7.41 (m, 3H), 7.52–7.54 
(m, 2H), 7.56 (d, J = 16.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 20.6 (CH3), 28.4 (3 × CH3), 43.8 
(CH), 46.6 (CH2), 79.2 (C), 126.4 (CH), 128.4 (2 × CH), 129.0 (2 × CH), 130.6 (CH), 134.4 (C), 143.2 
(CH), 155.2 (C), 198.9 (C); MS (ESI) m/z 312 (MNa+, 100); HRMS (ESI) calcd for C17H23NNaO3 
(MNa+), 312.1570, found 312.1558. 
(2R,5E)-6-(4’-Methoxyphenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9e). The reaction was 
carried out according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-
1-(dimethyloxyphosphoryl)pentan-2-one (8) (0.241 g, 0.781 mmol) and anisaldehyde (0.190 mL, 1.56 
mmol) for 96 h. Purification by flash column chromatography on silica gel, eluting with 20% ethyl 
acetate in petroleum ether (40–60) gave (2R,5E)-6-(4’-methoxyphenyl)-2-(tert-butoxycarbonylamino)-
4-oxohex-5-ene (9e)  (0.186 g, 75%) as a white solid. Mp 102–105 °C; Rf 0.10 (20% ethyl acetate in 
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petroleum ether); IR (neat) 3375, 2980, 1682, 1600, 1511 cm−1; [α]D23 +50.1 (c 1.0, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 1.24 (d, J = 6.8 Hz, 3H), 1.43 (s, 9H), 2.74 (dd, J = 15.7, 6.8 Hz, 1H), 2.97 (dd, J = 
15.7, 4.5 Hz, 1H), 3.84 (s, 3H), 4.04–4.16 (m, 1H), 5.03 (br s, 1H), 6.62 (d, J = 16.1 Hz, 1H), 6.91 (d, J 
= 8.7 Hz, 2H), 7.50 (d, J = 8.7 Hz, 2H), 7.54 (d, J = 16.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 20.6 
(CH3), 28.4 (3 × CH3), 43.9 (CH), 46.4 (CH2), 55.4 (CH3), 79.2 (C), 114.4 (2 × CH), 124.2 (CH), 127.0 
(C), 130.1 (2 × CH), 143.1 (CH), 155.2 (C), 161.7 (C), 198.8 (C); MS (ESI) m/z 342 (MNa+, 100); 
HRMS (ESI) calcd for C18H25NNaO4 (MNa
+), 342.1676, found 342.1661.  
(2R,5E)-6-(Naphthalen-2’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9f). The reaction was 
carried out according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-
1-(dimethyloxyphosphoryl)pentan-2-one (8) (0.262 g, 0.849 mmol) and 2-naphthaldehyde (0.265 g, 
1.70 mmol) for 48 h. Purification by flash column chromatography on silica gel, eluting with 30% ethyl 
acetate in petroleum ether (40–60) gave (2R,5E)-6-(naphthalen-2’-yl)-2-(tert-butoxycarbonylamino)-4-
oxohex-5-ene (9f) (0.231 g, 80%) as a white solid. Mp 103–106 °C; Rf 0.35 (30% ethyl acetate in 
petroleum ether); IR (neat) 3358, 2972, 1683, 1518, 1364 cm−1; [α]D23 +30.4 (c 1.0, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 1.27 (d, J = 6.7 Hz, 3H), 1.44 (s, 9H), 2.81 (dd, J = 15.9, 6.7 Hz, 1H), 3.04 (dd, J = 
15.9, 4.4 Hz, 1H), 4.07–4.21 (m, 1H), 5.00 (br s, 1H), 6.85 (d, J = 16.1 Hz, 1H), 7.48–7.56 (m, 2H), 
7.68 (dd, J = 8.6, 1.2 Hz, 1H), 7.75 (d, J = 16.1 Hz, 1H), 7.81–7.90 (m, 3H), 7.97 (br s, 1H); 13C NMR 
(101 MHz, CDCl3) δ 20.6 (CH3), 28.4 (3 × CH3), 43.9 (CH), 46.7 (CH2), 79.2 (C), 123.5 (CH), 126.4 
(CH), 126.8 (CH), 127.4 (CH), 127.8 (CH), 128.6 (CH), 128.7 (CH), 130.5 (CH), 131.9 (C), 133.3 (C), 
134.4 (C), 143.2 (CH), 155.2 (C), 198.8 (C); MS (ESI) m/z 362 (MNa+, 100); HRMS (ESI) calcd for 
C21H25NNaO3 (MNa
+), 362.1727, found 362.1710. 
(2R,5E)-6-(4’-Nitrophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9g). The reaction was 
carried out according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-
1-(dimethyloxyphosphoryl)pentan-2-one (8) (0.209 g, 0.676 mmol) and 4-nitrobenzaldehyde (0.204 g, 
1.35 mmol) for 6 h. Purification by flash column chromatography on silica gel, eluting with 30% ethyl 
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acetate in petroleum ether (40–60) gave (2R,5E)-6-(4’-nitrophenyl)-2-(tert-butoxycarbonylamino)-4-
oxohex-5-ene (9g)  (0.143 g, 63%) as a pale yellow solid. Mp 122–126 °C; Rf 0.19 (30% ethyl acetate in 
petroleum ether); IR (neat) 3365, 2980, 1683, 1612, 1514 cm−1; [α]D26 +14.7 (c 1.0, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 1.27 (d, J = 6.7 Hz, 3H), 1.43 (s, 9H), 2.80 (dd, J = 15.8, 6.7 Hz, 1H), 3.06 (dd, J = 
15.8, 4.2 Hz, 1H), 4.07–4.20 (m, 1H), 4.94 (br s, 1H), 6.86 (d, J = 16.2 Hz, 1H), 7.63 (d, J = 16.2 Hz, 
1H), 7.72 (d, J = 8.8 Hz, 2H), 8.26 (d, J = 8.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 20.6 (CH3), 28.4 
(3 × CH3), 43.8 (CH), 47.4 (CH2), 79.4 (C), 124.2 (2 × CH), 128.9 (2 × CH), 129.6 (CH), 140.0 (CH), 
140.7 (C), 148.6 (C), 155.2 (C), 198.2 (C); MS (ESI) m/z 357 (MNa+, 100); HRMS (ESI) calcd for 
C17H22N2NaO5 (MNa
+), 357.1421, found 357.1405. 
(2R,5E)-6-(Pyridin-3’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9h). The reaction was 
carried out according to the procedure for the synthesis of 9a using (4R)-4-(tert-butoxycarbonylamino)-
1-(dimethyloxyphosphoryl)pentan-2-one (8) (0.212 g, 0.687 mmol) and 3-pyridinecarboxaldehyde 
(0.130 mL, 1.37 mmol) for 24 h. Purification by flash column chromatography on silica gel, eluting 
with 40% ethyl acetate in dichloromethane gave (2R,5E)-6-(pyridin-3’-yl)-2-(tert-
butoxycarbonylamino)-4-oxohex-5-ene (9h) (0.130 g, 65%) as an off-white solid. Mp 93–96 °C; Rf 0.1 
(40% ethyl acetate in dichloromethane); IR (neat) 3362, 2970, 1678, 1519, 1365 cm−1; [α]D26 +6.0 (c 
1.0, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.26 (d, J = 6.8 Hz, 3H), 1.43 (s, 9H), 2.78 (dd, J = 15.8, 
6.8 Hz, 1H), 3.03 (dd, J = 15.8, 4.6 Hz, 1H), 4.06–4.19 (m, 1H), 5.03 (br s, 1H), 6.81 (d, J = 16.3 Hz, 
1H), 7.35 (dd, J = 7.9, 4.1 Hz, 1H), 7.59 (d, J = 16.3 Hz, 1H), 7.85–7.91 (m, 1H), 8.62 (d, J = 4.1 Hz, 
1H), 8.77 (br s, 1H); 13C NMR (101 MHz, CDCl3) δ 20.6 (CH3), 28.4 (3 × CH3), 43.8 (CH), 47.1 (CH2), 
79.3 (C), 123.8 (CH), 128.0 (CH), 130.3 (C), 134.4 (CH), 139.3 (CH), 150.1 (CH), 151.2 (CH), 155.2 
(C), 198.3 (C); MS (ESI) m/z 313 (MNa+, 100); HRMS (ESI) calcd for C16H22N2NaO3 (MNa
+), 
313.1523, found 313.1513. 
(2R,6S)-2-Methyl-6-propylpiperidin-4-one (10a) and (2R,6R)-2-methyl-6-propylpiperidin-4-one 
(11a). (2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (9a) (0.298 g, 1.17 mmol) was 
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dissolved in dichloromethane (12 mL) and trifluoroacetic acid (0.890 mL, 11.7 mmol) was added 
dropwise. The mixture was stirred for 1.5 h at room temperature. The mixture was then concentrated in 
vacuo and the crude residue was redissolved in methanol (12 mL) and cooled to 0 °C. N,N-
Diisopropylethylamine (0.300 mL, 1.75 mmol) was added dropwise and the mixture was allowed to 
warm to room temperature and left to stir for 2 h. The mixture was then diluted with ethyl acetate (15 
mL) and washed with a saturated aqueous solution of sodium hydrogen carbonate (10 mL) and brine (10 
mL). The organic layer was dried over MgSO4 and concentrated in vacuo. Purification by flash column 
chromatography on silica gel (soaked with 1% triethylamine/dichloromethane), with a gradient elution 
from 40% ethyl acetate/10% dichloromethane/1% triethylamine in petroleum ether (40–60) to 40% 
ethyl acetate/30% dichloromethane/1% triethylamine in petroleum ether (40–60) gave (2R,6S)-2-
methyl-6-propylpiperidin-4-one (10a) (0.0780 g, 43%) as a dark orange oil. Further elution yielded 
(2R,6R)-2-methyl-6-propylpiperidin-4-one (11a) (0.0760 g, 42%) as a dark orange oil. Data for (2R,6S)-
2-methyl-6-propylpiperidin-4-one (10a): Rf 0.47 (40% ethyl acetate/30% dichloromethane/1% 
triethylamine in petroleum ether); IR (neat) 3302, 2962, 1658, 1527 cm−1; [α]D26 +9.8 (c 0.2, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 0.93 (t, J = 7.2 Hz, 3H), 1.21 (d, J = 6.2 Hz, 3H), 1.29–1.68 (m, 5H), 1.99–
2.12 (m, 2H), 2.30–2.39 (m, 2H), 2.85 (tdd, J = 9.1, 6.2, 2.9 Hz, 1H), 2.96 (dqd, J = 12.4, 6.2, 2.9 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 14.1 (CH3), 18.9 (CH2), 22.7 (CH3), 39.2 (CH2), 48.2 (CH2), 50.2 
(CH2), 52.1 (CH), 56.3 (CH), 209.6 (C); MS (ESI) m/z 156 (MH
+, 100); HRMS (ESI) calcd for 
C9H18NO (MH
+), 156.1383, found 156.1377. Data for (2R,6R)-2-methyl-6-propylpiperidin-4-one (11a): 
Rf 0.23 (40% ethyl acetate/30% dichloromethane/1% triethylamine in petroleum ether); IR (neat) 3271, 
2954, 1720, 1535 cm−1; [α]D26 −7.9 (c 0.1, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.92 (t, J = 7.1 Hz, 
3H), 1.16 (d, J = 6.5 Hz, 3H), 1.23–1.52 (m, 4H), 1.61 (br s, 1H), 2.14 (dddd, J = 13.6, 11.6, 6.0, 1.6 
Hz, 2H), 2.47 (dddd, J = 15.6, 14.0, 5.2, 1.6 Hz, 2H), 3.27–3.36 (m, 1H), 3.39–3.49 (m, 1H); 13C NMR 
(101 MHz, CDCl3) δ 13.9 (CH3), 19.3 (CH2), 21.6 (CH3), 36.9 (CH2), 47.8 (CH2 and CH), 49.6 (CH2), 
52.3 (CH), 210.0 (C); MS (ESI) m/z 156 (MH+, 100); HRMS (ESI) calcd for C9H18NO (MH
+), 
156.1383, found 156.1378. 
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(2R,6S)-2-Methyl-6-nonylpiperidin-4-one (10b)5d and (2R,6R)-2-methyl-6-nonylpiperidin-4-one 
(11b). The reaction was carried out according to the procedure for the synthesis of 10a and 11a using 
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxopentadec-5-ene (9b) (0.30 g, 0.89 mmol). Purification by 
flash column chromatography on silica gel, (soaked with 1% triethylamine/petroleum ether) eluting with 
20% ethyl acetate/1% triethylamine in petroleum ether (40–60) gave (2R,6S)-2-methyl-6-
nonylpiperidin-4-one (10b) (0.095 g, 45%) as an orange oil. Further elution yielded (2R,6R)-2-methyl-
6-nonylpiperidin-4-one (11b) (0.093 g, 44%) as an orange oil. Data for (2R,6S)-2-methyl-6-
nonylpiperidin-4-one (10b): Rf 0.22 (20% ethyl acetate/1% triethylamine in petroleum ether); [α]D26 
−2.4 (c 1.0, CHCl3), lit.5d [α]D22 −1.5 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.2 Hz, 
3H), 1.21 (d, J = 5.8 Hz, 3H), 1.23–1.61  (m, 17H), 1.99–2.12 (m, 2H), 2.24–2.45 (m, 2H), 2.77–2.89 
(m, 1H), 2.90–3.04 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 14.1 (CH3), 22.7 (CH3 and CH2), 25.7 
(CH2), 29.3 (CH2), 29.5 (2 × CH2), 29.6 (CH2), 31.9 (CH2), 37.1 (CH2), 48.2 (CH2), 50.2 (CH2), 52.1 
(CH), 56.6 (CH), 209.6 (C); MS (ESI) m/z 240 (MH+, 100). Data for (2R,6R)-2-methyl-6-
nonylpiperidin-4-one (11b): Rf 0.07 (20% ethyl acetate/1% triethylamine in petroleum ether); IR (neat) 
3300, 2958, 1710, 1458 cm−1; [α]D26 −3.5 (c 1.0, CHCl3); 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.3 
Hz, 3H), 1.16 (d, J = 6.4 Hz, 3H), 1.20–1.54 (m, 17H), 2.09–2.20 (m, 2H), 2.42–2.54 (m, 2H), 3.24–
3.34 (m, 1H), 3.39–3.49 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 14.1 (CH3), 21.7 (CH3), 22.7 (CH2), 
26.1 (CH2), 29.3 (CH2), 29.5 (CH2), 29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 34.8 (CH2), 47.8 (CH), 47.8 
(CH2), 49.6 (CH2), 52.7 (CH), 210.0 (C); MS (ESI) m/z 240 (MH
+, 100); HRMS (ESI) calcd for 
C15H30NO (MH
+), 240.2322, found 240.2316.  
(2R,6S)-2-Methyl-6-(2’-phenylethyl)piperidin-4-one (10c) and (2R,6R)-2-methyl-6-(2’-
phenylethyl)piperidin-4-one (11c). The reaction was carried out according to the procedure for the 
synthesis of 10a and 11a using (2R,5E)-8-phenyl-2-(tert-butoxycarbonylamino)-4-oxooct-5-ene (9c) 
(0.133 g, 0.420 mmol). Purification by flash column chromatography on silica gel (soaked with 1% 
triethylamine/petroleum ether), with a gradient elution from 60% ethyl acetate/1% triethylamine in 
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petroleum ether (40–60) to 90% ethyl acetate/1% triethylamine in petroleum ether (40–60) gave 
(2R,6S)-2-methyl-6-(2’-phenylethyl)piperidin-4-one (10c) (0.0380 g, 42%) as a brown oil. Further 
elution yielded (2R,6R)-2-methyl-6-(2’-phenylethyl)piperidin-4-one (11c) (0.0360 g, 40%) as a brown 
oil. Data for (2R,6S)-2-methyl-6-(2’-phenylethyl)piperidin-4-one (10c): Rf 0.32 (60% ethyl acetate/1% 
triethylamine in petroleum ether); IR (neat) 3300, 2960, 1714, 1454 cm−1; [α]D26 +2.2 (c 1.0, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 1.20 (d, J = 6.2 Hz, 3H), 1.67 (br s, 1H), 1.75–1.91 (m, 2H), 2.04–2.14 (m, 
2H), 2.34 (dt, J = 15.0, 5.0 Hz, 1H), 2.41 (dt, J = 15.0, 5.0 Hz, 1H), 2.70 (t, J = 8.0 Hz, 2H), 2.84–2.98 
(m, 2H), 7.15–7.32 (m, 5H); 13C NMR (126 MHz, CDCl3) δ 22.6 (CH3), 32.2 (CH2), 38.6 (CH2), 48.1 
(CH2), 50.2 (CH2), 52.0 (CH), 56.1 (CH), 126.1 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.4 (C), 209.2 
(C); MS (ESI) m/z 218 (MH+, 100); HRMS (ESI) calcd for C14H20NO (MH
+), 218.1539, found 
218.1540. Data for (2R,6R)-2-methyl-6-(2’-phenylethyl)piperidin-4-one (11c): Rf 0.11 (60% ethyl 
acetate/1% triethylamine in petroleum ether); IR (neat) 3300, 2926, 1708, 1454 cm−1; [α]D26 +6.0 (c 1.0, 
CHCl3); 
1H NMR (500 MHz, CDCl3) δ 1.14 (d, J = 6.5 Hz, 3H), 1.68–1.86 (m, 3H), 2.13 (ddd, J = 13.8, 
7.3, 1.4 Hz, 1H), 2.21 (ddd, J = 13.8, 6.0, 1.4 Hz, 1H), 2.47 (ddd, J = 13.8, 4.6, 1.4 Hz, 1H), 2.52 (ddd, J 
= 13.8, 5.1, 1.4 Hz, 1H), 2.61–2.73 (m, 2H), 3.31–3.38 (m, 1H), 3.40–3.48 (m, 1H), 7.15–7.31 (m, 5H); 
13C NMR (126 MHz, CDCl3) δ 21.6 (CH3), 32.5 (CH2), 36.2 (CH2), 47.8 (CH2), 47.8 (CH), 49.7 (CH2), 
52.3 (CH), 126.0 (CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.4 (C), 209.6 (C); MS (ESI) m/z 218 (MH+, 
100); HRMS (ESI) calcd for C14H20NO (MH
+), 218.1539, found 218.1537. 
(2R,6R)-2-Methyl-6-phenylpiperidin-4-one (10d)16b and (2R,6S)-2-methyl-6-phenylpiperidin-4-one 
(11d). The reaction was carried out according to the procedure for the synthesis of 10a and 11a using 
(2R,5E)-6-phenyl-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9d) (0.105 g, 0.365 mmol), 
dichloromethane (4 mL) and trifluoroacetic acid (0.279 mL, 3.65 mmol). Purification by flash column 
chromatography on silica gel (soaked with 1% triethylamine/petroleum ether), with a gradient elution 
from 30% ethyl acetate/1% triethylamine in petroleum ether (40–60) to 60% ethyl acetate/1% 
triethylamine in petroleum ether (40–60) gave (2R,6R)-2-methyl-6-phenylpiperidin-4-one (10d) (0.0290 
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g, 42%) as an orange solid. Further elution yielded (2R,6S)-2-methyl-6-phenylpiperidin-4-one (11d) 
(0.0280 g, 40%) as an orange solid. Data for (2R,6R)-2-methyl-6-phenylpiperidin-4-one (10d): Mp 58–
61 °C; Rf 0.30 (30% ethyl acetate/1% triethylamine in petroleum ether); [α]D26 +69.4 (c 0.9, CHCl3), 
lit.16b [α]D20 +72.2 (c 0.9, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.26 (d, J = 6.1 Hz, 3H), 1.80 (br s, 
1H), 2.23 (dd, J = 14.0, 11.9 Hz, 1H), 2.41 (dd, J = 14.0, 2.7 Hz, 1H), 2.47–2.53 (m, 2H), 3.12 (dqd, J = 
11.9, 6.1, 2.7 Hz, 1H), 3.96 (dt, J = 11.9, 8.0 Hz, 1H), 7.27–7.43 (m, 5H); 13C NMR (101 MHz, CDCl3) 
δ 22.7 (CH3), 49.8 (CH2), 50.0 (CH2), 52.4 (CH), 61.1 (CH), 126.5 (2 × CH), 127.9 (CH), 128.8 (2 × 
CH), 142.7 (C), 208.9 (C); MS (ESI) m/z 190 (MH+, 100). Data for (2R,6S)-2-methyl-6-
phenylpiperidin-4-one (11d): Mp 65–69 °C; Rf 0.06 (30% ethyl acetate/1% triethylamine in petroleum 
ether); IR (neat) 3309, 2962, 1712, 1450 cm−1; [α]D26 +8.2 (c 0.2, CHCl3); 1H NMR (400 MHz, CDCl3) 
δ 1.19 (d, J = 6.4 Hz, 3H), 1.82 (br s, 1H), 2.23 (ddd, J = 14.2, 6.4, 1.1 Hz, 1H), 2.59–2.73 (m, 3H), 
3.41–3.51 (m, 1H), 4.48 (t, J = 8.0 Hz, 1H), 7.25–7.41 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 21.2 
(CH3), 47.8 (CH), 47.8 (CH2), 48.9 (CH2), 55.6 (CH), 126.9 (2 × CH), 127.6 (CH), 128.7 (2 × CH), 
142.7 (C), 209.5 (C); MS (ESI) m/z 190 (MH+, 100); HRMS (ESI) calcd for C12H16NO (MH
+), 
190.1226, found 190.1226. 
(2R,6R)-2-Methyl-6-(4’-methoxyphenyl)piperidin-4-one (10e) and (2R,6S)-2-methyl-6-(4’-
methoxyphenyl)piperidin-4-one (11e). The reaction was carried out according to the procedure for the 
synthesis of 10a and 11a using (2R,5E)-6-(4’-methoxyphenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-
5-ene (9e) (0.18 g, 0.56 mmol). Purification by flash column chromatography on silica gel (soaked with 
1% triethylamine/petroleum ether), with a gradient elution from 40% ethyl acetate/1% triethylamine in 
petroleum ether (40–60) to 80% ethyl acetate/1% triethylamine in petroleum ether (40–60) gave 
(2R,6R)-2-methyl-6-(4’-methoxyphenyl)piperidin-4-one (10e) (0.056 g, 46%) as an orange solid. 
Further elution yielded (2R,6S)-2-methyl-6-(4’-methoxyphenyl)piperidin-4-one (11e) (0.045 g, 37%) as 
a red solid. Data for (2R,6R)-2-methyl-6-(4’-methoxyphenyl)piperidin-4-one (10e): Mp 83–85 °C; Rf 
0.22 (40% ethyl acetate/1% triethylamine in petroleum ether); IR (neat) 3300, 2966, 1708, 1510 cm−1; 
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[α]D26 +65.3 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.25 (d, J = 6.2 Hz, 3H), 1.79 (br s, 1H), 
2.21 (dd, J = 14.0, 11.9 Hz, 1H), 2.39 (dd, J = 14.0, 2.6 Hz, 1H), 2.44–2.51 (m, 2H), 3.10 (dqd, J = 11.9, 
6.2, 2.6 Hz, 1H), 3.80 (s, 3H), 3.90 (dd, J = 8.6, 6.2 Hz, 1H), 6.87–6.91 (m, 2H), 7.30–7.34 (m, 2H); 13C 
NMR (126 MHz, CDCl3) δ 22.6 (CH3), 49.8 (CH2), 50.1 (CH2), 52.3 (CH), 55.3 (CH3), 60.5 (CH), 
114.1 (2 × CH), 127.7 (2 × CH), 134.9 (C), 159.2 (C), 209.0 (C); MS (ESI) m/z 220 (MH+, 100); HRMS 
(ESI) calcd for C13H18NO2 (MH
+), 220.1332, found 220.1327. Data for (2R,6S)-2-methyl-6-(4’-
methoxyphenyl)piperidin-4-one (11e): Mp 78–80 °C; Rf 0.070 (40% ethyl acetate/1% triethylamine in 
petroleum ether); IR (neat) 3300, 2823, 1705, 1512 cm−1; [α]D26 +34.7 (c 0.2, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 1.18 (d, J = 6.5 Hz, 3H), 1.76 (br s, 1H), 2.22 (ddd, J = 14.2, 6.5, 1.1 Hz, 1H), 2.58–
2.70 (m, 3H), 3.39–3.48 (m, 1H), 3.80 (s, 3H), 4.44 (t, J = 6.5 Hz, 1H), 6.85–6.90 (m, 2H), 7.23–7.29 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 21.2 (CH3), 47.7 (CH), 48.0 (CH2), 48.9 (CH2), 55.1 (CH3), 
55.3 (CH), 114.0 (2 × CH), 128.0 (2 × CH), 134.8 (C), 158.9 (C), 209.7 (C); MS (ESI) m/z 220 (MH+, 
100); HRMS (ESI) calcd for C13H18NO2 (MH
+), 220.1332, found 220.1331. 
(2R,6R)-2-Methyl-6-(naphthalen-2’-yl)piperidin-4-one (10f) and (2R,6S)-2-methyl-6-(naphthalen-
2’-yl)piperidin-4-one (11f). The reaction was carried out according to the procedure for the synthesis of 
10a and 11a using (2R,5E)-6-(naphthalen-2’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9f) 
(0.13 g, 0.39 mmol). Purification by flash column chromatography on silica gel (soaked with 1% 
triethylamine/petroleum ether), with a gradient elution from 40% ethyl acetate/1% triethylamine in 
petroleum ether (40–60) to 1% triethylamine in ethyl acetate gave (2R,6R)-2-methyl-6-(naphthalen-2’-
yl)piperidin-4-one (10f) (0.041 g, 44%) as an orange oil. Further elution yielded (2R,6S)-2-methyl-6-
(naphthalen-2’-yl)piperidin-4-one (11f) (0.039 g, 42%) as an orange oil. Data for (2R,6R)-2-methyl-6-
(naphthalen-2’-yl)piperidin-4-one (10f): Rf 0.39 (40% ethyl acetate/1% triethylamine in petroleum 
ether); IR (neat) 3311, 2970, 1714, 1373 cm−1; [α]D26 +65.9 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) 
δ 1.29 (d, J = 6.2 Hz, 3H), 1.91 (br s, 1H), 2.27 (dd, J = 14.0, 11.9 Hz, 1H), 2.44 (dd, J = 14.0, 2.7 Hz, 
1H), 2.57 (d, J = 8.0 Hz, 2H), 3.17 (dqd, J = 11.9, 6.2, 2.7 Hz, 1H), 4.08–4.15 (m, 1H), 7.45–7.51 (m, 
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2H), 7.52 (dd, J = 8.6, 1.5 Hz, 1H), 7.80–7.86 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 22.7 (CH3), 49.8 
(CH2), 49.9 (CH2), 52.4 (CH), 61.1 (CH), 124.7 (CH), 125.1 (CH), 126.0 (CH), 126.3 (CH), 127.7 
(CH), 127.9 (CH), 128.5 (CH), 133.1 (C), 133.4 (C), 140.0 (C), 208.7 (C); MS (ESI) m/z 240 (MH+, 
100); HRMS (ESI) calcd for C16H18NO (MH
+), 240.1383, found 240.1379. Data for (2R,6S)-2-methyl-
6-(naphthalen-2’-yl)piperidin-4-one (11f): Rf 0.10 (40% ethyl acetate/1% triethylamine in petroleum 
ether); IR (neat) 3315, 2964, 1708, 1506, 1305 cm−1; [α]D26 −58.7 (c 1.0, CHCl3); 1H NMR (500 MHz, 
CDCl3) δ 1.20 (d, J = 6.6 Hz, 3H), 1.86 (br s, 1H), 2.26 (ddd, J = 14.2, 6.6, 1.4 Hz, 1H), 2.65 (ddd, J = 
14.2, 4.9, 1.4 Hz, 1H), 2.74 (ddd, J = 14.4, 5.3, 1.4 Hz, 1H), 2.81 (ddd, J = 14.4, 6.9, 1.4 Hz, 1H), 3.41–
3.49 (m, 1H), 4.65 (dd, J = 6.9, 5.3 Hz, 1H), 7.45–7.51 (m, 3H), 7.75 (br s, 1H), 7.79–7.86 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 21.1 (CH3), 47.4 (CH2), 47.8 (CH), 48.8 (CH2), 55.7 (CH), 125.1 (CH), 
125.6 (CH), 126.1 (CH), 126.4 (CH), 127.6 (CH), 128.0 (CH), 128.6 (CH), 132.8 (C), 133.2 (C), 139.5 
(C), 208.6 (C); MS (ESI) m/z 240 (MH+, 100); HRMS (ESI) calcd for C16H18NO (MH
+), 240.1383, 
found 240.1386. 
(2R,6R)-2-Methyl-6-(4’-nitrophenyl)piperidin-4-one (10g) and (2R,6S)-2-methyl-6-(4’-
nitrophenyl)piperidin-4-one (11g). The reaction was carried out according to the procedure for the 
synthesis of 10a and 11a using (2R,5E)-6-(4’-nitrophenyl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-
ene (9g) (0.103 g, 0.309 mmol). Purification by flash column chromatography on silica gel (soaked with 
1% triethylamine/petroleum ether), eluting with 40% ethyl acetate/1% triethylamine in petroleum ether 
(40–60) gave (2R,6R)-2-methyl-6-(4’-nitrophenyl)piperidin-4-one (10g) (0.0310 g, 43%) as a red solid. 
Further elution yielded (2R,6S)-2-methyl-6-(4’-nitrophenyl)piperidin-4-one (11g) (0.0300 g, 41%) as a 
brown solid. Data for (2R,6R)-2-methyl-6-(4’-nitrophenyl)piperidin-4-one (10g): Mp 117–120 °C; Rf 
0.21 (40% ethyl acetate/1% triethylamine in petroleum ether); IR (neat) 3321, 2968, 1705, 1510, 1346 
cm−1; [α]D26 +62.4 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.29 (d, J = 6.1 Hz, 3H), 1.86 (br s, 
1H), 2.25 (ddd, J = 14.0, 12.0, 0.8 Hz, 1H), 2.37–2.54 (m, 3H), 3.15 (dqd, J = 12.0, 6.1, 2.9 Hz, 1H), 
4.09 (dd, J = 11.8, 3.2 Hz, 1H), 7.58–7.64 (m, 2H), 8.19–8.26 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 
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22.6 (CH3), 49.6 (CH2), 49.7 (CH2), 52.2 (CH), 60.3 (CH), 124.1 (2 × CH), 127.4 (2 × CH), 147.5 (C), 
149.9 (C), 207.4 (C); MS (ESI) m/z 235 (MH+, 100); HRMS (ESI) calcd for C12H15N2O3 (MH
+), 
235.1077, found 235.1073. Data for (2R,6S)-2-methyl-6-(4’-nitrophenyl)piperidin-4-one (11g): Mp 88–
91 °C; Rf 0.07 (40% ethyl acetate/1% triethylamine in petroleum ether); IR (neat) 3300, 2962, 1707, 
1508, 1344 cm−1; [α]D26 +11.1 (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.22 (d, J = 6.6 Hz, 3H), 
1.82 (br s, 1H), 2.26 (ddd, J = 14.0, 6.1, 1.0 Hz, 1H), 2.61–2.72 (m, 3H), 3.42–3.50 (m, 1H), 4.59 (t, J = 
5.0 Hz, 1H), 7.55–7.60 (m, 2H), 8.18–8.23 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 21.1 (CH3), 47.7 
(CH2), 48.2 (CH), 48.9 (CH2), 55.2 (CH), 123.9 (2 × CH), 127.8 (2 × CH), 147.3 (C), 150.0 (C), 208.3 
(C); MS (ESI) m/z 235 (MH+, 100); HRMS (ESI) calcd for C12H15N2O3 (MH
+), 235.1077, found 
235.1075. 
(2R,6R)-2-Methyl-6-(pyridin-3’-yl)piperidin-4-one (10h) and (2R,6S)-2-methyl-6-(pyridin-3’-
yl)piperidin-4-one (11h). The reaction was carried out according to the procedure for the synthesis of 
10a and 11a using (2R,5E)-6-(pyridin-3’-yl)-2-(tert-butoxycarbonylamino)-4-oxohex-5-ene (9h) (0.096 
g, 0.33 mmol). Purification by flash column chromatography on silica gel (soaked with 1% 
triethylamine/dichloromethane), eluting with 2% methanol/50% dichloromethane/1% triethylamine in 
petroleum ether (40–60) gave (2R,6R)-2-methyl-6-(pyridin-3’-yl)piperidin-4-one (10h) (0.026 g, 41%) 
as an orange oil. Further elution yielded (2R,6S)-2-methyl-6-(pyridin-3’-yl)piperidin-4-one (11h) (0.025 
g, 39%) as an orange oil. Data for (2R,6R)-2-methyl-6-(pyridin-3’-yl)piperidin-4-one (10h): Rf 0.22 (2% 
methanol/50% dichloromethane/1% triethylamine in petroleum ether); IR (neat) 3285, 2965, 1709, 1426 
cm−1; [α]D26 +70.5 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.27 (d, J = 6.1 Hz, 3H), 1.85 (br s, 
1H), 2.23 (dd, J 14.0, 10.6 Hz, 1H), 2.40–2.54 (m, 3H), 3.14 (dqd, J = 12.2, 6.1, 2.9 Hz, 1H), 4.01 (dd, J 
= 10.6, 4.4 Hz, 1H), 7.31 (dd, J = 7.9, 4.8 Hz, 1H), 7.77 (dt, J = 7.9, 1.9 Hz, 1H), 8.56 (dd, J = 4.8, 1.9 
Hz, 1H), 8.64 (br d, J = 1.9 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 22.6 (CH3), 49.6 (CH2), 49.6 
(CH2), 52.4 (CH), 58.6 (CH), 123.7 (CH), 134.2 (CH), 138.0 (C), 148.5 (CH), 149.5 (CH), 207.9 (C); 
MS (ESI) m/z 191 (MH+, 100); HRMS (ESI) calcd for C11H15N2O (MH
+), 191.1179, found 191.1181. 
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Data for (2R,6S)-2-methyl-6-(pyridin-3’-yl)piperidin-4-one (11h): Rf 0.11 (2% methanol/50% 
dichloromethane/1% triethylamine in petroleum ether); IR (neat) 3263, 2962, 1705, 1419 cm−1; [α]D26 
+38.9 (c 0.2, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.22 (d, J = 6.4 Hz, 3H), 1.69 (br s, 1H), 2.26 (dd, 
J = 14.1, 6.4 Hz, 1H), 2.62–2.70 (m, 3H), 3.42–3.52 (m, 1H), 4.54 (t, J = 6.2 Hz, 1H), 7.28 (dd, J 7.9, 
4.8 Hz, 1H), 7.70 (dt, J = 7.9, 1.8 Hz, 1H), 8.54 (dd, J = 4.8, 1.8 Hz, 1H), 8.64 (d, J = 1.8 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 21.0 (CH3), 47.5 (CH2), 48.1 (CH), 48.8 (CH2), 53.6 (CH), 123.5 (CH), 
134.4 (CH), 137.8 (C), 148.9 (CH), 149.1 (CH), 208.4 (C); MS (ESI) m/z 191 (MH+, 100); HRMS (ESI) 
calcd for C11H15N2O (MH
+), 191.1179, found 191.1178. 
(2R,4S,6S)-2-Methyl-6-propylpiperidin-4-ol (1).7a (2R,6S)-2-Methyl-6-propylpiperidin-4-one (10a) 
(0.094 g, 0.061 mmol) was dissolved in anhydrous methanol (2 mL) and cooled to −15 °C. Sodium 
borohydride (0.0046 g, 0.12 mmol) was added and the solution was stirred rapidly for 0.25 h. Brine (1 
mL) was added to quench the reaction and the mixture was diluted with ethyl acetate (10 mL). The 
organic layer was washed with brine (5 mL), dried over MgSO4 and concentrated in vacuo. Purification 
by flash column chromatography on silica gel, eluting with 30% methanol/1% triethylamine in ethyl 
acetate gave (2R,4S,6S)-2-methyl-6-propylpiperidin-4-ol (1) (0.080 g, 87%) as an off-white solid. Mp 
74–76 °C; Rf 0.25 (30% methanol/1% triethylamine in ethyl acetate); [α]D26 +9.0 (c 0.7, MeOH), lit.7a 
[α]D20 +8.8 (c 0.4, MeOH); 1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 7.1 Hz, 3H), 0.98 (q, J = 11.8 Hz, 
1H), 1.03 (q, J = 11.8 Hz, 1H), 1.12 (d, J = 6.3 Hz, 3H), 1.29–1.46 (m, 4H), 1.86 (br s, 2H), 1.91–2.01 
(m, 2H), 2.52–2.61 (m, 1H), 2.69 (dqd, J = 11.8, 6.3, 2.4 Hz, 1H), 3.65 (tt, J = 11.8, 4.5 Hz, 1H); 13C 
NMR (101 MHz, CDCl3) δ 14.2 (CH3), 19.2 (CH2), 22.4 (CH3), 38.9 (CH2), 41.6 (CH2), 43.9 (CH2), 
50.2 (CH), 54.6 (CH), 69.3 (CH); MS (ESI) m/z 158 (MH+, 100). 
(2R,4S,6S)-2-Methyl-6-nonylpiperidin-4-ol (2).5a The reaction was carried out according to the 
procedure for the synthesis of 1 using (2R,6S)-2-methyl-6-nonylpiperidin-4-one (10b) (0.028 g, 0.12 
mmol). Purification by flash column chromatography on silica gel, eluting with 10% methanol/1% 
triethylamine in ethyl acetate gave (2R,4S,6S)-2-methyl-6-nonylpiperidin-4-ol (2) (0.023 g, 84%) as an 
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off-white solid. Mp 86–88 °C; Rf 0.16 (10% methanol/1% triethylamine in ethyl acetate); [α]D26 +7.9 (c 
1.0, MeOH), lit.5a [α]D25 +7.0 (c 1.0, MeOH); 1H NMR (500 MHz, CDCl3) δ 0.88 (t, J = 7.0 Hz, 3H), 
0.93–1.06 (m, 2H), 1.12 (d, J = 6.3 Hz, 3H), 1.20–1.48 (m, 16H), 1.63 (br s, 2H), 0.97 (q, J = 11.8 Hz, 
1H), 1.02 (q, J = 11.8 Hz, 1H), 2.50–2.58 (m, 1H), 2.68 (dqd, J = 11.8, 6.3, 2.4 Hz, 1H), 3.65 (tt, J = 
11.8, 4.6 Hz, 1H); 13C NMR (126 MHz, CDCl3) δ 14.1 (CH3), 22.5 (CH3), 22.7 (CH2), 26.1 (CH2), 29.3 
(CH2), 29.6 (CH2), 29.6 (CH2), 29.8 (CH2), 31.9 (CH2), 36.8 (CH2), 41.8 (CH2), 43.9 (CH2), 50.2 (CH), 
54.9 (CH), 69.4 (CH); MS (ESI) m/z 242 (MH+, 100). 
(2R,4S,6S)-2-Methyl-6-(2’-phenylethyl)piperidin-4-ol (12a).21 The reaction was carried out according 
to the procedure for the synthesis of 1 using (2R,6S)-2-methyl-6-(2’-phenylethyl)piperidin-4-one (10c) 
(0.014 g, 0.063 mmol). Purification by flash column chromatography on silica gel, eluting with 1% 
methanol/1% triethylamine in dichloromethane gave (2R,4S,6S)-2-methyl-6-(2’-phenylethyl)piperidin-
4-ol (12a) (0.011 g, 80%) as an off-white solid. Spectroscopic data was consistent with the literature.21 
Mp 98–102 °C; Rf 0.19 (1% methanol/1% triethylamine in dichloromethane); [α]D26 +7.0 (c 0.6, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.02 (q, J = 11.7 Hz, 1H), 1.04 (q, J = 11.7 Hz, 1H), 1.12 (d, J = 
6.3 Hz, 3H), 1.47 (br s, 2H), 1.67–1.83 (m, 2H), 1.95 (ddt, J = 11.7, 4.5, 2.2 Hz, 1H), 2.03 (ddt, J = 
11.7, 4.5, 2.2 Hz, 1H), 2.56–2.72 (m, 4H), 3.66 (tt, J = 11.7, 4.5 Hz, 1H), 7.16–7.21 (m, 3H), 7.25–7.31 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 22.5 (CH3), 32.4 (CH2), 38.5 (CH2), 41.7 (CH2), 43.9 (CH2), 
50.1 (CH), 54.4 (CH), 69.3 (CH), 125.9 (CH), 128.3 (2 × CH), 128.4 (2 × CH), 142.0 (C); MS (ESI) m/z 
220 (MH+, 100). 
(2R,4S,6R)-2-Methyl-6-phenylpiperidin-4-ol (12b).22 The reaction was carried out according to the 
procedure for the synthesis of 1 using (2R,6R)-2-methyl-6-phenylpiperidin-4-one (10d) (0.015 g, 0.077 
mmol). Purification by flash column chromatography on silica gel, eluting with 1% methanol/1% 
triethylamine in dichloromethane gave (2R,4S,6R)-2-methyl-6-phenylpiperidin-4-ol (12b) (0.013 g, 
91%) as an off white solid. Mp 92–94 °C; Rf 0.19 (1% methanol/1% triethylamine in dichloromethane); 
[α]D26 +27.6 (c 1.0, CHCl3), lit.22 [α]D20 +29.0 (c 0.5, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1.10–1.21 
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(m, 4H), 1.45 (q, J = 11.8 Hz, 1H), 1.58 (br s, 2H), 2.00 (ddt, J = 11.8, 4.6, 2.4 Hz, 1H), 2.10 (ddt, J = 
11.8, 4.6, 2.4 Hz, 1H), 2.86 (dqd, J = 11.8, 6.3, 2.4 Hz, 1H), 3.69 (dd, J = 11.8, 2.4 Hz, 1H), 3.81 (tt, J = 
11.8, 4.6 Hz, 1H), 7.23–7.41 (m, 5H); 13C NMR (101 MHz, CDCl3) δ 22.5 (CH3), 43.4 (CH2), 43.4 
(CH2), 50.7 (CH), 59.8 (CH), 69.8 (CH), 126.8 (2 × CH), 127.3 (CH), 128.5 (2 × CH), 144.0 (C); MS 
(ESI) m/z 192 (MH+, 100). 
(2R,4S,6R)-2-Methyl-6-(4’-methoxyphenyl)piperidin-4-ol (12c). The reaction was carried out 
according to the procedure for the synthesis of 1 using (2R,6R)-2-methyl-6-(4’-
methoxyphenyl)piperidin-4-one (10e) (0.0170 g, 0.0780 mmol). Purification by flash column 
chromatography on silica gel, eluting with 70% ethyl acetate/1% triethylamine in dichloromethane gave 
(2R,4S,6R)-2-methyl-6-(4’-methoxyphenyl)piperidin-4-ol (12c) (0.015 g, 85%) as a white solid. Mp 85–
90 °C; Rf 0.11 (70% ethyl acetate/1% triethylamine in dichloromethane); IR (neat) 3340, 2933, 1514, 
1303 cm−1; [α]D26 +21.3 (c 1.0, CHCl3); 1H NMR (500 MHz, CDCl3) δ 1.09–1.19 (m, 4H), 1.43 (q, J = 
12.0 Hz, 1H), 1.61 (br s, 2H), 1.99 (ddt, J = 12.0, 4.4, 2.3 Hz, 1H), 2.07 (ddt, J = 12.0, 4.4, 2.3 Hz, 1H), 
2.84 (dqd, J = 12.0, 6.2, 2.3 Hz, 1H), 3.64 (dd, J = 12.0, 2.3 Hz, 1H), 3.75–3.83 (m, 4H), 6.83–6.89 (m, 
2H), 7.27–7.32 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 22.5 (CH3), 43.4 (2 × CH2), 50.7 (CH), 55.3 
(CH3), 59.1 (CH), 69.8 (CH), 113.8 (2 × CH), 127.8 (2 × CH), 136.3 (C), 158.8 (C); MS (ESI) m/z 222 
(MH+, 95); HRMS (ESI) calcd for C13H20NO2 (MH
+), 222.1489, found 222.1487. 
(2R,4S,6R)-2-Methyl-6-(naphthalen-2’-yl)piperidin-4-ol (12d). The reaction was carried out 
according to the procedure for the synthesis of 1 using (2R,6R)-2-methyl-6-(naphthalen-2’-yl)piperidin-
4-one (10f) (0.036 g, 0.15 mmol). Purification by flash column chromatography on silica gel, eluting 
with 80% ethyl acetate/1% triethylamine in dichloromethane gave (2R,4S,6R)-2-methyl-6-(naphthalen-
2’-yl)piperidin-4-ol (12d) (0.032 g, 88%) as a white solid. Mp 157–160 °C; Rf 0.21 (80% ethyl 
acetate/1% triethylamine in dichloromethane); IR (neat) 3284, 2926, 1599, 1371 cm−1; [α]D26 +6.9 (c 
1.0, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 1.12–1.26 (m, 4H), 1.53 (q, J = 12.2 Hz, 1H), 1.68 (br s, 
2H), 2.03 (ddt, J = 12.2, 4.5, 2.3 Hz, 1H), 2.18 (ddt, J = 12.2, 4.5, 2.3 Hz, 1H), 2.90 (dqd, J = 12.2, 6.3, 
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2.3 Hz, 1H), 3.80–3.90 (m, 2H), 7.41–7.53 (m, 3H), 7.77–7.86 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 
22.5 (CH3), 43.5 (CH2), 43.5 (CH2), 50.8 (CH), 59.8 (CH), 69.8 (CH), 125.0 (CH), 125.3 (CH), 125.6 
(CH), 126.0 (CH), 127.6 (CH), 127.9 (CH), 128.1 (CH), 132.9 (C), 133.5 (C), 141.5 (C); MS (ESI) m/z 
242 (MH+, 100); HRMS (ESI) calcd for C16H20NO (MH
+), 242.1539, found 242.1538. 
(2R,4S,6R)-2-Methyl-6-(4’-nitrophenyl)piperidin-4-ol (12e). The reaction was carried out according 
to the procedure for the synthesis of 1 using (2R,6R)-2-methyl-6-(4’-nitrophenyl)piperidin-4-one (10g) 
(0.019 g, 0.082 mmol). Purification by flash column chromatography on silica gel, eluting with 70% 
ethyl acetate/1% triethylamine in petroleum ether (40–60) gave (2R,4S,6R)-2-methyl-6-(4’-
nitrophenyl)piperidin-4-ol (12e) (0.015 g, 75%) as a yellow oil. Rf 0.12 (70% ethyl acetate/1% 
triethylamine in petroleum ether); IR (neat) 3298, 2935, 1516, 1344 cm−1; [α]D26 +20.0 (c 0.9, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 1.12–1.22 (m, 4H), 1.37 (q, J = 12.3 Hz, 1H), 1.58 (br s, 2H), 2.03 (ddt, J 
= 12.3, 4.5, 2.4 Hz, 1H), 2.10 (ddt, J = 12.3, 4.5, 2.4 Hz, 1H), 2.89 (dqd, J = 12.3, 6.2, 2.4 Hz, 1H), 
3.79–3.88 (m, 2H), 7.54–7.58 (m, 2H), 8.16–8.21 (m, 2H); 13C NMR (126 MHz, CDCl3) δ 22.5 (CH3), 
43.1 (CH2), 43.5 (CH2), 50.5 (CH), 59.2 (CH), 69.4 (CH), 123.8 (2 × CH), 127.6 (2 × CH), 147.2 (C), 
151.6 (C); MS (ESI) m/z 237 (MH+, 100); HRMS (ESI) calcd for C12H17N2O3 (MH
+), 237.1234, found 
237.1239. 
(2R,4S,6R)-2-Methyl-6-(pyridin-3’-yl)piperidin-4-ol (12f). The reaction was carried out according to 
the procedure for the synthesis of 1 using (2R,6R)-2-methyl-6-(pyridin-3’-yl)piperidin-4-one (10h) 
(0.018 g, 0.092 mmol). Purification by flash column chromatography on silica gel, eluting with 5% 
methanol/1% triethylamine in dichloromethane gave (2R,4S,6R)-2-methyl-6-(pyridin-3’-yl)piperidin-4-
ol (12f) (0.012 g, 68%) as a pale yellow oil. Rf 0.23 (5% methanol/1% triethylamine in 
dichloromethane); IR (neat) 3254, 2933, 1425, 1305 cm−1; [α]D26 +17.7 (c 0.8, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 1.10–1.23 (m, 4H), 1.44 (q, J = 12.2 Hz, 1H), 1.87 (br s, 2H), 2.02 (ddt, J = 12.2, 4.5, 
2.3 Hz, 1H), 2.09 (ddt, J = 12.2, 4.5, 2.3 Hz, 1H), 2.88 (dqd, J = 12.2, 6.2, 2.3 Hz, 1H), 3.74 (dd, J = 
12.2, 2.3 Hz, 1H), 3.82 (tt, J = 12.2, 4.5 Hz, 1H), 7.26 (dd, J = 7.9, 4.8 Hz, 1H), 7.74 (dt, J = 7.9, 1.8 
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Hz, 1H), 8.50 (dd, J = 4.8, 1.8 Hz, 1H), 8.58 (d, J = 1.8 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 22.5 
(CH3), 43.2 (2 × CH2), 50.7 (CH), 57.3 (CH), 69.4 (CH), 123.6 (CH), 134.4 (CH), 139.4 (C), 148.7 
(CH), 148.8 (CH); MS (ESI) m/z 193 (MH+, 100); HRMS (ESI) calcd for  C11H17N2O (MH
+), 193.1335, 
found 193.1339.  
 
SUPPORTING INFORMATION. NOE data of all novel cyclic compounds and, 1H and 13C NMR 
spectra for all compounds. This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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